Why Argenx's (ARGX) Stock Price Moved Up 11% on Thursday

Shares of Argenx (ARGX) rose 11.2% on Mar 21, after Japan-based Chugai Pharmaceutical posted disappointing results from a late-stage study evaluating Enspryng (satralizumab) as a potential treatment for generalized myasthenia gravis (gMG). This drug has been developed in collaboration with Roche (RHHBY) .The Tokyo-based company evaluated the Roche-partnered drug in the phase III LUMINESCE study in patients with gMG, a rare autoimmune disease that leads to muscle weakness. While patients who received the Chu ...